Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 4.79 USD 2.35% Market Closed
Market Cap: 921.2m USD

Operating Margin
Arbutus Biopharma Corp

-233.3%
Current
-541%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-233.3%
=
Operating Profit
-34.1m
/
Revenue
14.6m

Operating Margin Across Competitors

No Stocks Found

Arbutus Biopharma Corp
Glance View

Market Cap
919.5m USD
Industry
Biotechnology

Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).

ABUS Intrinsic Value
0.46 USD
Overvaluation 90%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-233.3%
=
Operating Profit
-34.1m
/
Revenue
14.6m
What is the Operating Margin of Arbutus Biopharma Corp?

Based on Arbutus Biopharma Corp's most recent financial statements, the company has Operating Margin of -233.3%.

Back to Top